mRNA-1345 respiratory syncytial virus vaccine clinical trials
Also written mRNA-1345.
Its developmentBy Moderna, step by step11 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses mRNA-1345 respiratory syncytial virus vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- mRNA-1345
- 11
Studies by the year they started
11 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 5 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
mRNA-1010 influenza vaccine (2) · mRNA-1273.214 COVID-19 vaccine (2) · MRNA-1365 (1) · 2019-nCoV Vaccine mRNA-1273 (1) · mRNA-1647 cytomegalovirus vaccine (1) · MRNA-1045 (1) · MRNA-1230 (1)
Studies
Open first, then newest update. How each study uses mRNA-1345 respiratory syncytial virus vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgeCompletedPhase 2/3ModernaTX, Inc.NCT05127434Written as mRNA-1345
- A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsCompletedPhase 3ModernaTX, Inc.NCT06067230Written as mRNA-1345
- A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial VirusCompletedPhase 2ModernaTX, Inc.NCT06097299Written as mRNA-1345
- A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsActive, not recruitingPhase 1ModernaTX, Inc.NCT05743881Written as mRNA-1345
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersCompletedPhase 2ModernaTX, Inc.NCT06143046Written as mRNA-1345
- A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT07117487Written as mRNA-1345
- A Study of Modified mRNA Vaccines in Healthy AdultsCompletedPhase 1ModernaTX, Inc.NCT05397223Written as mRNA-1345
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT05330975Written as mRNA-1345
- A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT06060457Written as mRNA-1345
- A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-SeropositiveCompletedPhase 1ModernaTX, Inc.NCT04528719Written as mRNA-1345
- A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years OldCompletedPhase 1ModernaTX, Inc.NCT05585632Written as mRNA-1345
Given beside what is tested · 1 — mRNA-1345 respiratory syncytial virus vaccine is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with mRNA-1345 respiratory syncytial virus vaccine
Codes
What other systems call mRNA-1345 respiratory syncytial virus vaccine · ClinicalTrials.gg INT001888
- MeSH (NLM) C000722749mRNA-1345 respiratory syncytial virus vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722749 | mRNA-1345 respiratory syncytial virus vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.